To overcome this limitation, numerous clinical trials have evaluated the efficacy of combinations with other agents, including anti-VEGF, in numerous types of cancer, such as non-small cell lung cancer, hepatocellular carcinoma and breast cancer (5,15,16). Here, VEGFA is linked to breast cancer.